What factors contributed to the 30% drop in Temasek's returns from its life sciences portfolio investments in the last fiscal year?

Introduction

Temasek's 30% drop in returns from its life sciences portfolio investments is a significant concern that requires a thorough root cause analysis. I'll approach this issue systematically, examining both internal and external factors that could have contributed to this performance decline. My analysis will cover market conditions, investment strategies, portfolio composition, and operational aspects of the life sciences companies within Temasek's portfolio.

Step 1

Clarifying Questions (3 minutes)

• Looking at the timing, I'm thinking there might be a specific event or market shift. Has there been any significant regulatory change or major scientific breakthrough in the life sciences sector during this period?

Why it matters: Regulatory changes or scientific advancements can dramatically impact the valuation and prospects of life sciences companies. Expected answer: Information about recent regulatory changes or major scientific developments. Impact on approach: This would help focus the analysis on specific sub-sectors or companies most affected by these changes.

• Considering portfolio composition, I'm wondering about diversification. How is Temasek's life sciences portfolio distributed across different sub-sectors (e.g., pharmaceuticals, biotechnology, medical devices)?

Why it matters: Different sub-sectors within life sciences can perform differently based on market conditions and technological advancements. Expected answer: A breakdown of portfolio allocation across life sciences sub-sectors. Impact on approach: This would help identify if the performance drop is concentrated in specific sub-sectors or widespread.

• Thinking about investment stages, are the majority of Temasek's life sciences investments in early-stage companies or more established firms?

Why it matters: Early-stage investments typically carry higher risk but also higher potential returns, while established firms might offer more stability. Expected answer: Information on the distribution of investments across different stages. Impact on approach: This would inform whether the risk profile of the portfolio aligns with Temasek's investment strategy and market conditions.

• Considering market dynamics, has there been a significant change in the valuation multiples for life sciences companies in the public markets during this period?

Why it matters: Public market valuations can significantly impact private market valuations and overall portfolio performance. Expected answer: Information on changes in public market valuations for life sciences companies. Impact on approach: This would help determine if the performance drop is primarily due to market sentiment or company-specific factors.